Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

rozanolixizumab 10 zilucoplan 7 ravulizumab 7 efgartigimod alfa 6 eculizumab 5 fludarabine 4 Cyclophosphamide 4 telitacicept 3 Tacrolimus 3 HBM9161 3 inebilizumab 2 Mycophenolic Acid 2 Diagnostic Self Evaluation 2 Amifampridine 2 satralizumab 1 rhoA GTP-Binding Protein 1 remibrutinib 1 iscalimab 1 iptacopan 1 Robotic Surgical Procedures 1 Prednisone 1 Prednisolone 1 Plasmapheresis 1 Immunoglobulins, Intravenous 1 Data Collection 1 Cladribine 1 CK-2017357 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Myasthenia Gravis × remibrutinib × Clear all

NCT06744920 2026-06-01

RELIEVE

Novartis

Phase 3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡